Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VRN101099 |
| Synonyms | |
| Therapy Description |
VRN101099 is a blood-brain barrier penetrant covalent inhibitor of ERBB2 (HER2), which decreases Erbb2 (Her2), Akt, and Erk phosphorylation and potentially inhibits tumor cell proliferation and tumor growth (Cancer Res (2023) 83 (5_Supplement): P1-11-03). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VRN101099 | HER2 Inhibitor 44 | VRN101099 is a blood-brain barrier penetrant covalent inhibitor of ERBB2 (HER2), which decreases Erbb2 (Her2), Akt, and Erk phosphorylation and potentially inhibits tumor cell proliferation and tumor growth (Cancer Res (2023) 83 (5_Supplement): P1-11-03). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06806982 | Phase I | VRN101099 | A Study of VRN101099 in Patients With HER2-Positive Solid Tumors | Recruiting | AUS | 0 |